Yn gyntaf, yn dilyn penderfyniad diweddar yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) i gymeradwyo brechlyn COVID-19 Pfizer-BioNTech (Comirnaty®) mewn plant iau, mae'r JCVI wedi argymell y dylai plant 5 i 11 oed – plant sy’n perthyn i un o’r grwpiau “risg” neu sy'n gyswllt cartref i rywun sy’n imiwnoataliedig – gael cynnig dau ddos 10 microgram o'r brechlyn Pfizer-BioNTech. Dylid gadael bwlch o wyth wythnos rhwng y dos cyntaf a'r ail ddos o’r brechlyn. Os bydd unigolyn wedi cael haint COVID-19 yn ddiweddar, dylid gadael bwlch o bedair wythnos o leiaf rhwng unrhyw ddos o frechlyn a’r haint hwnnw.
Firstly, following the recent decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) vaccine in younger children, the JCVI has recommended children aged 5 to 11, who are in an “at-risk” group or are the household contact of someone who is immunosuppressed should be offered two 10 micrograms doses of the Pfizer-BioNTech vaccine with an interval of eight weeks between the first and second doses. The minimum interval between any vaccine dose and recent COVID-19 infection should be four weeks.